Fnu Sadarat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fnu Sadarat has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hong Yu Wang
Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, USA
1 shared publication - Lorenzo Leys
Department of Internal Medicine, Mount Sinai Beth Israel, New York, NY 10003, USA
1 shared publication - Puja Mehta
Department of Nephrology (P.M.), Yale School of Medicine, Section of Nephrology New Haven, CT
1 shared publication - Roopa Kumari
Department of Pathology, Mount Sinai Morningside, and Mount Sinai West, New York, NY 10025, USA
1 shared publication - Subhash Chander
Department of Internal Medicine, Mount Sinai Beth Israel, New York, NY 10003, USA
1 shared publication - Vishal Deepak
Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, West Virginia University, Morgantown, WV, USA
1 shared publication
Latest Publications
- Open Access
- 28 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2555
Glycemic Control in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis
Background: Given the mortality risk in COVID-19 patients, it is necessary to estimate the impact of glycemic control on mortality rates among inpatients by designing and implementing evidence-based blood glucose (BG) control methods. There is evidence to suggest that COVID-19 patients with hyperglycemia are at risk of mortality, and glycemic control may improve outcomes. However, the optimal target range of blood glucose levels in critically ill COVID-19 patients remains unclear, and further research is needed to establish the most effective glycemic control strategies in this population. Methods: The investigation was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data sources were drawn from Google Scholar, ResearchGate, PubMed (MEDLINE), Cochrane Library, and Embase databases. Randomized controlled trials, non-randomized controlled trials, retrospective cohort studies, and observational studies with comparison groups specific to tight glycemic control in COVID-19 patients with and without diabetes. Results: Eleven observational studies (26,953 patients hospitalized for COVID-19) were included. The incidence of death was significantly higher among COVID-19 patients diagnosed with diabetes than those without diabetes (OR = 2.70 [2.11, 3.45] at a 95% confidence interval). Incidences of death (OR of 3.76 (3.00, 4.72) at a 95% confidence interval) and complications (OR of 0.88 [0.76, 1.02] at a 95% confidence interval) were also significantly higher for COVID-19 patients with poor glycemic control. Conclusion: These findings suggest that poor glycemic control in critically ill patients leads to an increased mortality rate, infection rate, mechanical ventilation, and prolonged hospitalization.
- 28 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (7) , 2555
Open AccessGlycemic Control in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis
Background: Given the mortality risk in COVID-19 patients, it is necessary to estimate the impact of glycemic control on mortality rates among inpatients by designing and implementing evidence-based blood glucose (BG) control methods. There is evidence to suggest that COVID-19 patients with hyperglycemia are at risk of mortality, and glycemic control may improve outcomes. However, the optimal target range of blood glucose levels in critically ill COVID-19 patients remains unclear, and further research is needed to establish the most effective glycemic control strategies in this population. Methods: The investigation was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Data sources were drawn from Google Scholar, ResearchGate, PubMed (MEDLINE), Cochrane Library, and Embase databases. Randomized controlled trials, non-randomized controlled trials, retrospective cohort studies, and observational studies with comparison groups specific to tight glycemic control in COVID-19 patients with and without diabetes. Results: Eleven observational studies (26,953 patients hospitalized for COVID-19) were included. The incidence of death was significantly higher among COVID-19 patients diagnosed with diabetes than those without diabetes (OR = 2.70 [2.11, 3.45] at a 95% confidence interval). Incidences of death (OR of 3.76 (3.00, 4.72) at a 95% confidence interval) and complications (OR of 0.88 [0.76, 1.02] at a 95% confidence interval) were also significantly higher for COVID-19 patients with poor glycemic control. Conclusion: These findings suggest that poor glycemic control in critically ill patients leads to an increased mortality rate, infection rate, mechanical ventilation, and prolonged hospitalization.